Corinne Abate-Shen

Title: Corinne Abate-Shen: Innovator in Prostate Cancer Treatment

Introduction

Corinne Abate-Shen is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of aggressive prostate cancer. Her innovative work has the potential to impact the lives of many patients facing this challenging disease.

Latest Patents

Corinne Abate-Shen holds a patent for a method and composition for the diagnosis or treatment of aggressive prostate cancer. This patent includes methods, pharmaceutical formulations, and medicaments aimed at treating prostate cancer or preventing the progression of a nonaggressive form of prostate cancer to an aggressive form. The invention involves a therapeutically effective amount of one or more active agents that reduce the expression or biological activity of both Forkhead box protein M1 (FOXM1) and Centromere protein F (CENPF). The patent also covers biologically active fragments selected from a group consisting of isolated shRNA, siRNA, antisense RNA, antisense DNA, Chimeric Antisense DNA/RNA, microRNA, and ribozymes that are sufficiently complementary to either a gene or an mRNA encoding either FOXM1 or CENPF proteins.

Career Highlights

Corinne Abate-Shen is affiliated with Columbia University, where she continues her research and development in cancer therapies. Her work has garnered attention for its innovative approach to tackling aggressive forms of prostate cancer.

Collaborations

She has collaborated with notable colleagues, including Andrea Califano and Michael Y Shen, to advance her research and explore new avenues in cancer treatment.

Conclusion

Corinne Abate-Shen's contributions to the field of prostate cancer treatment exemplify the impact of innovative research in medicine. Her patent and ongoing work at Columbia University highlight her commitment to improving patient outcomes in oncology.